Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 5/20 | 0.35 |
| ▸ | FNTB | P49356 | 5/20 | 0.35 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6056363 | 0.92 | ALDH1A1 (0.35) | FNTAFNTBHDAC3HDAC4HDAC1 | |
| SCHEMBL6056535 | 0.85 | FNTA (0.49) | KMT2AFNTAFNTBPGGT1BALDH1A1 | |
| SCHEMBL6056476 | 0.81 | FNTA (0.39) | KMT2AMEN1FNTAFNTBPGGT1B | |
| SCHEMBL6056422 | 0.79 | EGFR (0.43) | KMT2AFNTAFNTBHDAC3HDAC4 | |
| SCHEMBL6056539 | 0.77 | FNTA (0.44) | KMT2AMEN1FNTAFNTBPGGT1B | |
| SCHEMBL7621361 | 0.77 | FNTA (0.57) | KMT2AFNTAFNTBPGGT1BHDAC3 | |
| SCHEMBL6056451 | 0.75 | FNTA (0.40) | FNTAFNTBTSHRUSP2ALDH1A1 | |
| SCHEMBL6056506 | 0.73 | FNTA (0.49) | KMT2AFNTAFNTBPGGT1B | |
| SCHEMBL6056460 | 0.73 | FNTB (0.64) | FNTAFNTBPGGT1BHDAC3HDAC1 | |
| SCHEMBL6056401 | 0.73 | FNTA (0.51) | KMT2AFNTAFNTBPGGT1BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0725650-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1999-02-03 | — | — | EP | claimed |
| EP-0725650-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO. INC. (US) | 1996-08-14 | — | — | EP | claimed |
| WO-1995009001-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1995-04-06 | — | — | WO | claimed |
| WO-2006017369-A2 | USE OF A FARNESYL TRANSFERASE INHIBITOR IN THE TREATMENT OF VIRAL INFECTIONS | GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20020006967-A1 | METHODS OF TREATMENT OF OCULAR NEOVASCULARIZATION | CAMPOCHIARO PETER A (US) | 2002-01-17 | — | — | US | disclosed |
| US-6160015-A | ADMINISTERING TO MAMMAL A FARNESYL PROTEIN TRANSFERASE INHIBITOR | UNIVERSITY OF CINCINNATI (US) | 2000-12-12 | — | — | US | disclosed |
| EP-0840605-A4 | COMPOUNDS USEFUL IN THE TREATMENT OF NEUROFIBROMATOSIS | UNIV CINCINNATI (US) | 2000-05-10 | — | — | EP | disclosed |
| EP-0725650-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1999-02-03 | — | — | EP | disclosed |
| WO-1998057654-A1 | METHODS FOR TREATMENT OF OCULAR NEOVASCULARIZATION | JOHNS HOPKINS UNIVERSITY (US) | 1998-12-23 | — | — | WO | disclosed |
| EP-0840605-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEUROFIBROMATOSIS | University of Cincinnati (US) | 1998-05-13 | — | — | EP | disclosed |
| EP-0836383-A1 | COMBINATIONS OF INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-04-22 | — | — | EP | disclosed |
| WO-1997002817-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEUROFIBROMATOSIS | UNIVERSITY OF CINCINNATI (US) | 1997-01-30 | — | — | WO | disclosed |
| US-5576293-A | TETRAPEPTIDES, ANTICARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1996-11-19 | — | — | US | disclosed |
| EP-0725650-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO. INC. (US) | 1996-08-14 | — | — | EP | disclosed |
| WO-1995009001-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1995-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006967-A1 | METHODS OF TREATMENT OF OCULAR NEOVASCULARIZATION | GGT1, FNTA, PIGO | KMT2A 3168/4885MEN1 4142/4885FNTA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.